Skip to main content

Table 2 Plasma or serum glucosepane free adduct in patients with early and advanced osteoarthritis and other early-stage arthritic disease

From: Glycation marker glucosepane increases with the progression of osteoarthritis and correlates with morphological and functional changes of cartilage in vivo

Study group No. Age (yr) Gender (M/F) Glucosepane (nM)
Control 29 34.4 ± 8.2 14/15 13.6 (10.1–18.1)
eOA 28 43.3 ± 13.3* 12/16 18.7 (13.3–35.5)*,OOO
aOA, pre-TKR 38 70.7 ± 8.9*** 15/23 76.3 (61.2–97.5)***
Non-RA 32 51.7 ± 18.1** 14/16 31.2 (20.3–45.2)**,OOO
eRA 35 60.4 ± 15.7*** 13/22 46.1 (31.1–77.8)***,OOO
  1. Abbreviations: eOA Early-stage osteoarthritis, aOA Advanced osteoarthritis, TKR Total knee replacement, RA Rheumatoid arthritis, eRA Early-stage rheumatoid arthritis
  2. Data are median (lower – upper quartile). Significance: 5-group comparison – p < 0.001 (Kruskal-Wallis). For binary comparisons: *, ** and ***, p < 0.05, p < 0.01 and p < 0.001 with respect to plasma levels of healthy controls; ooo, p < 0.001 with respect to plasma levels of aOA, pre-TKR (Mann-Whitney U)